Clopidogrel of loading dosage to treat acute ischaemic stroke in China (CLASS-CHINA): A randomized double-blind parallel controlled clinical trial

Jinan University Guangzhou (China)0 个研究点目标入组 600 人开始时间: 2008年3月14日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Aged 18-80 years
•2. Ischemic stroke (IS) within 48 hrs with evidence of computerised tomography (CT) or magnetic resonance imaging (MRI)
•3. Satisfying the criteria of partial anterior circulation infarction (PACI) of Oxfordshire Community Stroke Project (OCSP) classification, and large artery atherothrombosis (LAA) of TOAST (the Trial of Org 10172 in Acute Stroke Treatment) classification
•4. Informed consent of patient

•1. Patients planned for thrombolysis
•2. Any of the following:
•2.1. Cardiogenic cerebral embolism
•2.2. Lacuna cerebral infarction
•2.3. Total anterior circulation cerebral infarction
•2.4. Posterior circulation cerebral infarction
•2.5. Cerebral infarction of the etiology rather than atherothrombosis and unidentified etiology
•3. History of allergic reaction to clopidogrel
•4. Patients regularly took oral anticoagulants (OAC), heparin or molecular weight heparin (LMWH), thienopyridine (clopidogrel or ticlopidine), aspirin (acetylsalicylic acid) >50 mg/d, Aggrenox® before the onset; or patients who need long-term use of drugs that affect platelet functions
•5. History of bleeding disorders; clinically significant or persistent thrompocytopenia or neutropenia.
•6. Women who are pregnant or breast-feeding
•7. Patients with planned surgery within the next 1 month; with a recent operation or trauma history.
•8. Severe systematic disorders i.e. heart, lung, liver, kidney diseases, or malignant tumor; or severe gastrointestinal disorder affecting the absorption of drug
•9. Enrolled in other clinical trials within the past 3 months

发起方

Jinan University Guangzhou (China)